Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.
Adv Drug Deliv Rev. 2013 Nov;65(11-12):1575-88. doi: 10.1016/j.addr.2013.07.004. Epub 2013 Jul 13.
Microfluidic platforms provide several unique advantages for drug development. In the production of drug carriers, physical properties such as size and shape, and chemical properties such as drug composition and pharmacokinetic parameters, can be modified simply and effectively by tuning the flow rate and geometries. Large numbers of carriers can then be fabricated with minimal effort and with little to no batch-to-batch variation. Additionally, cell or tissue culture models in microfluidic systems can be used as in vitro drug screening tools. Compared to in vivo animal models, microfluidic drug screening platforms allow for high-throughput and reproducible screening at a significantly lower cost, and when combined with current advances in tissue engineering, are also capable of mimicking native tissues. In this review, various microfluidic platforms for drug and gene carrier fabrication are reviewed to provide guidelines for designing appropriate carriers. In vitro microfluidic drug screening platforms designed for high-throughput analysis and replication of in vivo conditions are also reviewed to highlight future directions for drug research and development.
微流控平台为药物开发提供了几个独特的优势。在药物载体的生产中,可以通过调整流速和几何形状,简单有效地改变载体的物理性质,如大小和形状,以及化学性质,如药物组成和药代动力学参数。然后可以用最小的努力和几乎没有批次间变化来制造大量的载体。此外,微流控系统中的细胞或组织培养模型可用作体外药物筛选工具。与体内动物模型相比,微流控药物筛选平台允许以更低的成本进行高通量和可重复的筛选,并且当与当前组织工程的进展相结合时,还能够模拟天然组织。在这篇综述中,我们回顾了各种用于药物和基因载体制造的微流控平台,为设计合适的载体提供了指导。我们还回顾了用于高通量分析和复制体内条件的体外微流控药物筛选平台,以突出药物研究和开发的未来方向。